Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Mar;82(5):1490-3.
doi: 10.1073/pnas.82.5.1490.

gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor

gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor

R Frade et al. Proc Natl Acad Sci U S A. 1985 Mar.

Abstract

The relationship between gp140, the membrane C3d receptor (CR2) of human B lymphocytes, and the Epstein-Barr virus receptor (EBVR) was analyzed by using the polyclonal anti-gp140, previously prepared by immunizing rabbits with highly purified gp140 (isolated by some of us) from CR2/EBVR-positive Raji cells. Polyclonal anti-gp72, a C3-binding membrane component, not related to the EBVR but also expressed on the Raji cell surface, was used as a control. Binding of rabbit IgG and EBV on cells was assessed by using immunofluorescence techniques with analysis by flow cytofluorometry. A semiquantitative bioassay was also used to measure the EBV binding. Polyclonal monospecific anti-gp140 IgG inhibits directly the binding of EBV to Raji cells at the same concentration that inhibits the binding of EC3d on cells, whereas a 35 times higher concentration of anti-gp72 IgG or preimmune serum IgG does not. Anti-gp140 IgG treatment also inhibits the induction of EBV-determined nuclear antigen in normal tonsil B lymphocytes or in EBV-negative Ramos cells, whereas high concentrations of anti-gp72 IgG or preimmune serum IgG have no effect. These data strongly suggest that gp140, the CR2 of human B lymphocytes, is also the EBVR.

PubMed Disclaimer

References

    1. J Immunol Methods. 1980;37(3-4):197-211 - PubMed
    1. Lancet. 1964 Feb 1;1(7327):238-40 - PubMed
    1. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1828-32 - PubMed
    1. FEBS Lett. 1981 Dec 21;136(1):111-4 - PubMed
    1. Eur J Immunol. 1982 Apr;12(4):289-94 - PubMed

Publication types

LinkOut - more resources